A Comparative Review of Current Therapeutic Approaches and Future Prospects of Rheumatoid Arthritis

Authors

  • Tianyue Zhang

DOI:

https://doi.org/10.54097/p7q3bd56

Keywords:

Rheumatoid arthritis, Therapeutic approaches, NSAIDs, Corticosteroid, DMARDs.

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects a large number of patients worldwide, causing enormous pain and imposing significant economic burdens on both individuals and society. Although the origin of RA remains unknown, evidence suggests that both genetic and environmental factors contribute to the disease. Once initiated, RA causes inflammation in the synovial joints, eventually leading to joint deformation and bone erosion. Currently, there is no definitive cure for RA; however, years of research and technological advances have provided numerous therapeutic approaches that can improve patients' conditions. Different patients respond differently to various therapies, making it important to summarize all categories of therapeutic approaches and their prospects. This review demonstrates the complex nature of RA by analyzing its etiology and pathogenesis. It then explains the major drugs used today and their comparative advantages. Potential treatments like CAR-T cell therapy, stem cell therapy, and nanotechnology-based approaches are also discussed, along with the challenges each method faces. This paper provides a general review of RA treatment and serves as a reference for future therapeutic research. Although the specific cause of RA remains unclear, this area could be an important direction for future study and holds the potential for achieving optimal treatment.

Downloads

Download data is not yet available.

References

[1] Black R.J. et al. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. The Lancet Rheumatology, 2023, 5(10): e594-e610.

[2] Pisetsky D.S. Pathogenesis of autoimmune disease. Nat Rev Nephrol, 2023, 19: 509–524.

[3] Khokhar M., Dey S., Tomo S., Jaremko M., Emwas A., Pandey R.K. Unveiling Novel Drug Targets and Emerging Therapies for Rheumatoid Arthritis: A comprehensive Review. ACS Pharmacology & Translational Science, 2024, 7(6): 1664-1693.

[4] Bullock J., Rizvi S.A.A., Saleh A.M., Ahmed S.S., Do D.P., Ansari R.A., Ahmed J. Rheumatoid Arthritis: A Brief Overview of the Treatment. Med Princ Pract, 2018, 27(6): 501-507.

[5] Guo Q., Wang Y., Xu D. et al. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res, 2018, 6: 15.

[6] Johns Hopkins Arthritis Center. Rheumatoid arthritis treatment. Johns Hopkins Medicine.

[7] Scherer H.U., Häupl T., Burmester G.R. The etiology of rheumatoid arthritis. Journal of Autoimmunity, 2020, 110: 102400.

[8] Woude V.D., Houwing-Duistermaat J.J., Toes R.E., Thomson T.W., Worthington J. Quantitative heritability of anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis. Arthritis Rheum, 2009, 60: 916-923.

[9] Hammer J., Gallazzi F., Bono E., Karr R.W., Guenot J., Valsasnini P. et al. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J Exp Med, 1995, 181: 1847-1855.

[10] Katherine P.L., Lars A., Elizabeth W.K. Environmental influences on risk for rheumatoid arthritis. Current Opinion in Rheumatology, 2009, 21(3): 279-283.

[11] Rantapaa-Dahlqvist S., de Jong B.A., Berglin E. et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum, 2003, 48: 2741–2749.

[12] Woude V.D. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis, 2010, 69: 1554–1561.

[13] Smolen J.S. EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2023, 82(1): 3-18.

[14] Crofford L. In: Kelley's Textbook of Rheumatology (2013). Prostanoid biology and its therapeutic targeting; pp. 871–893.

[15] Crofford L.J., Lipsky P.E., Brooks P., Abramson S.B., Simon L.S., van de Putte L.B.A. Basic biology and clinical application of specific COX-2 inhibitors. Arthritis Rheum, 2000, 15: 4–13.

[16] Crofford L.J. Use of NSAIDs in treating patients with arthritis, National Library of Medicine, July 24, 2013;15(suppl 3): S2.

[17] Doumen M., Pazmino S., Bertrand D., Westhovens R., Verschueren P. Glucocorticoids in rheumatoid arthritis: Balancing benefits and harm by leveraging the therapeutic window of opportunity. Joint Bone Spine, 2023, Volume 90, Issue 3: 105491.

[18] Benjamin O., Goyal A., Lappin S.L. Disease-Modifying Antirheumatic Drugs (DMARD) [Updated July 3, 2023]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; January, 2025.

[19] Idriss H.T., Naismith J.H. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech, August 1, 2000; 50(3): 184-95.

[20] Oo W.M., Yu S.P., Daniel M.S., Hunter D.J. Disease-modifying drugs in osteoarthritis: current understanding and future therapeutics. Expert Opin Emerg Drugs, December, 2018; 23(4): 331-347.

[21] Foley J.O., DuBois F.S Quantitative studies of the vagus nerve in the cat: I.The ratio of sensory to motor fibers. J Nerv Ment Dis,1937;86:587.

[22] Goggins E., Mitani S., Tanaka S Clinical perspective on vagus nerve stimulation: present and future. Clin Sci(Loud), May10,2022; 136(9): 695-709.

[23] Guffroy A., Jacquel L., Guffroy B., Martin T.CAR-T cells for treating systemic lupus erythematosus: A promising emerging therapy. Joint Bone Spine, 2024; 91(5): 105702.

[24] Sun L., Su Y., Jiao A.et al.T cells in health and disease. Sig Transduct Target Ther, 2023; 8: 235.

[25] Zhang C., Ma P., Qin A.et al. Current Immunotherapy Strategies for Rheumatoid Arthritis: The Immunoengineering and Delivery Systems.Research,2023;6:0220.

[26] Ren S., Xu Y., Dong X.et al. Nanotechnology-empowered combination therapy for rheumatoid arthritis: principles, strategies, and challenges. J Nanobiotechnol, 2024; 22: 431.

[27] Wei H, Wu Q, Shi Y.et al. MicroRNA-15a/16/SOX5 axis promotes migration, invasion and inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes. Aging (Albany NY), July17, 2020; 12: 14376-14390.

[28] Seegobin S.D., Ma M.H., Dahanayake C.et al. ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial. Arthritis Res Ther, 2014; 16: R13.

Downloads

Published

27-06-2025

How to Cite

Zhang, T. (2025). A Comparative Review of Current Therapeutic Approaches and Future Prospects of Rheumatoid Arthritis. Highlights in Science, Engineering and Technology, 144, 69-76. https://doi.org/10.54097/p7q3bd56